Skip to main content
Signal8
Launch Terminal

Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

NASDAQ:ALZNHealthcare
-0.82%$1.21
AH$1.21+0.00%vs close
Mkt Cap$5.84M
Float4.7M
O/S4.83M
Vol
$ Vol
RVOL
Inst Own52.0%
Earnings
Dilution
Alzamend Neuro, Inc. logoNASDAQ:ALZN$1.21-0.82%
Pipeline4 lead-sponsored trials·2 active2 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 1/2
    Completed

    Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

    AL001

    Alzheimer's Disease, Healthy Non-elderly and Elderly Adults

    Enrollment
    65
    Start
    May 2022
    Primary Completion
    Apr 2023
    Completion
    May 2023
    NCT05363293
  • Phase 1/2
    Active, not recruiting

    Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

    ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo

    Alzheimer Disease

    Enrollment
    30
    Start
    Jul 2023
    Primary Completion
    Mar 2028est.
    Completion
    Mar 2028est.
    NCT05834296
  • Phase 1/2
    Recruiting

    A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

    AL001, Lithium carbonate

    Bipolar I Disorder

    Enrollment
    20
    Start
    May 2026
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT07540338
  • Phase 1
    Completed

    A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

    AL001, Lithium Carbonate Capsule

    Pharmacokinetics, Neurology

    Enrollment
    15
    Start
    May 2025
    Primary Completion
    Dec 2025
    Completion
    Dec 2025
    NCT06921590
Search ClinicalTrials.gov for “Alzamend Neuro”